Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2017
SIETES contiene 92130 citas

 
 
 1 a 20 de 1915 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Casassus B. Contraception implant removed from global market. Lancet 2017;390:1576. [Ref.ID 102079]
2. Cita con resumen
Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: how the European Union pharmacovigilance system works. Drug Saf 2017;40:855-69. [Ref.ID 102075]
3. Cita con resumen
Edwards IR. A new Erice report considering the safety of medicines in the 21st Century. Drug Saf 2017;40:845-9. [Ref.ID 102074]
4.Enlace a cita original Cita con resumen
MacDonald A. EU drugs watchdog staff favor move to Amsterdam: sources. Reuters Health News 2017:1. [Ref.ID 102067]
5. Cita con resumen
6. Cita con resumen
de Vries ST, van der Sar MJM, Cupelli A, Baldelli I, Coleman AM, Montero D, Sipic I, Andric A, Wennberg A, Ahlqvist-Rastad J, Denig P, Mol PGM, On behalf of SCOPE Work Package 6. Communication on safety of medicines in Europe: current practices and general practitioners’ awareness and preferences. Drug Saf 2017;40:729-42. [Ref.ID 101983]
7. Cita con resumen
Kurz X. Advancing regulatory science, advancing regulatory practice. Pharmacoepidemiol Drug Saf 2017;26:722-6. [Ref.ID 101964]
8. Cita con resumen
Wallerstedt SM, Fastbom J, Linke J, Vitols S. Long-term use of proton pump inhibitors and prevalence of disease - and drug-related reasons for gastroprotection — A cross-sectional population-based study. Pharmacoepidemiol Drug Saf 2017;26:9-16. [Ref.ID 101946]
9.Enlace a cita original Cita con resumen
Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. Pharmacoepidemiol Drug Saf 2017:26 de marzo. [Ref.ID 101903]
10. Cita con resumen
Anónimo. EMA’s CHMP recommends approval of biosimilar insulin lispro. DIA Daily 2017:2. [Ref.ID 101598]
12. Cita con resumen
13. Cita con resumen
Anónimo. MSF, Medecins du Monde challenge Gilead’s sofosbuvir patent. DIA Daily 2017:1. [Ref.ID 101490]
14. Cita con resumen
Anónimo. Rivaroxaban: agranulocytoses et syndromes de Stevens-Johnson. Prescrire 2017;37:187. [Ref.ID 101456]
15. Cita con resumen
Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]
16. Cita con resumen
Anónimo. FDA approves fewest new drugs last year since 2010. DIA Daily 2017:2. [Ref.ID 101018]
17. Cita con resumen
Erviti López J, Saiz Fernández LC, Garjón Parra J. Fiabilidad de los ensayos clínicos. El peligroso camino de la desregulación de los medicamentos. Med Clin (Barc) 2016;147:554-7. [Ref.ID 101012]
18. Cita con resumen
Anónimo. EU approves palbociclib for treatment of breast cancer. DIA Daily 2016:2. [Ref.ID 100919]
19.Enlace a cita original Cita con resumen
Bouvy JC, Huinink L, De Bruin ML. Benefit-risk reassessment of medicines: a retrospective analysis of all safety-related referral procedures in Europe during 2001–2012. Pharmacoepidemiol Drug Saf 2016;25:1004-14. [Ref.ID 100902]
Seleccionar todas
 
 1 a 20 de 1915 siguiente >>